Premas Biotech is an Indian biologics-focused CDMO based in Gurugram, Haryana, with 150+ employees. They specialize in recombinant protein expression and manufacturing across multiple host systems: bacterial (E. coli), yeast (S. cerevisiae, Pichia pastoris), and mammalian (CHO-DG44). They have proprietary technology platforms including D-CRYPT (difficult-to-express proteins), AXTEX-4D (4D cell culture for oncology drug screening), and C-QWENCE (naive human phage scFv antibody library). Services span cell line development, scouting, process development, scale-up and GMP manufacturing, and analytical development with functional assays. They have delivered 650+ proteins with scale-up to 100L+ volumes and capacity to deliver grams to kilograms. Received a Gates Foundation grant for rotavirus vaccine development. Joint venture Oravax Medical (with Oramed Pharmaceuticals) for oral COVID-19 vaccine development using VLP technology.
recombinant protein expression (bacterial, yeast, mammalian), difficult-to-express proteins (D-CRYPT platform), cell line development (CHO-DG44, Pichia, E. coli), VLP vaccine development, monoclonal antibody production, lyophilization cycle development
1 site worldwide
No reviews available yet.
No documents available.